New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 24, 2014
07:24 EDTADXS, VRTX, RNA, RARE, PLX, NPSP, NLNK, ISIS, GEVA, FOLD, CYTK, CNAT, XOMACanaccord to hold a conference
Orphan Drugs 1:1 Day will be held in New York on February 24.
Check below for free stories on ADXS;CNAT;CYTK;FOLD;GEVA;ISIS;NLNK;NPSP;PLX;RARE;RNA;VRTX;XOMA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
September 9, 2014
08:17 EDTNPSPNPS Pharmaceuticals likely volatile on briefing docs, says FBR Capital
Subscribe for More Information
07:43 EDTADXSAdvaxis provides clinical development updatefor ADXS-HPV
Subscribe for More Information
September 8, 2014
14:37 EDTNPSPNPS Pharmaceuticals September volatility elevated into PDUFA
Subscribe for More Information
11:05 EDTNPSP, VRTXOptions with increasing implied volatility
Options with increasing implied volatility: NPSP GILD VNET AVNR GTAT YHOO RHT VRTX SDRL COV MYL
08:12 EDTRNAProsensa reports positive results from DEMAND II study of drisapersen
Subscribe for More Information
September 5, 2014
11:47 EDTNPSPOptions with increasing implied volatility
Subscribe for More Information
10:32 EDTNPSPNPS Pharmaceuticals September volatility increases into PDUFA
Subscribe for More Information
10:05 EDTVRTXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
05:41 EDTVRTXVertex upgraded to Buy from Neutral at Goldman
Goldman Sachs upgraded Vertex Pharmaceuticals to Buy saying it sees a 90% probability of approval for the company's VX-809/Kalydeco combo for cystic fibrosis and a higher likelihood of M&A following the positive Phase 3 data in June. Goldman raised its price target for shares to $131 from $109.
September 4, 2014
13:17 EDTRNASarepta rises after FDA seeks comment on proposed DMD drug guidance
Subscribe for More Information
10:45 EDTNPSPNPS drops after Feuerstein tweets about interview offer
Subscribe for More Information
10:06 EDTNPSPNPS Pharmaceuticals September volatility elevated into PDUFA
NPS Pharmaceuticals September call option implied volatility is at 96, October is at 71, November is at 68; compared to its 26-week average of 64 according to Track Data, suggesting large near term price movement into PDUFA for Natpara on September 12.
09:06 EDTNLNKOn The Fly: Pre-market Movers
UP AFTER EARNINGS: PVH Corp. (PVH), up 9%... Verifone (PAY), up 3.8%... Methode Electronics (MEI), up 13%... Bazaarvoice (BV), up 9%. ALSO HIGHER: Bolt Technology (BOLT), up 35.7% after Teledyne (TDY) agrees to acquire the company for $22 per share in cash... Mitek Systems (MITK), up 58% after USAA lawsuit settlement... Tibco Software (TIBX), up 7% after announcing that it is reviewing strategic alternatives... Stereotaxis (STXS), up 22% after receiving FDA clearance for Vdrive with V-Loop system... NewLink (NLNK), up 3.4% after reporting FDA approval for Phase 1 clinical studies of Ebola vaccine. DOWN AFTER EARNINGS: Ciena (CIEN), down 3%... Joy Global (JOY), down 1%... Matrix Service (MTRX), down 11%... Mobileye (MBLY), down 1.3%. ALSO LOWER: Yum! Brands (YUM), down 2.8% after updating third quarter China division same-store sales guidance... 3D Systems (DDD), down 2.9% after downgraded at Pacific Crest... GoPro (GPRO), down 3.5% after downgraded at JPMorgan... Shanda Games (GAME), down 4% after announcing reconstitution of special committee.
07:23 EDTNLNKNewLink reports FDA approval for Phase 1 clinical studies of Ebola vaccine
Subscribe for More Information
September 3, 2014
09:14 EDTRAREUltragenyx announces positive interim data from Phase 1/2 study of rhGUS
Ultragenyx Pharmaceutical announced the presentation of positive interim data from the Phase 1/2 study of recombinant human beta-glucuronidase, or rhGUS, UX003, an investigational therapy for the treatment of mucopolysaccharidosis 7, or MPS 7, Sly syndrome. The data are being presented at the Society for the Study of Inborn Errors of Metabolism, or SSIEM, Annual Symposium in Innsbruck, Austria. The Phase 1/2 open-label clinical study is assessing the safety, efficacy, and dose of rhGUS administered every other week via intravenous infusion in three patients. A 12-week primary analysis phase evaluating 2 mg/kg of rhGUS every other week is being followed by dose-exploration and long-term extension.
05:33 EDTCNATConatus management to meet with JMP Securities
Subscribe for More Information
September 2, 2014
19:28 EDTISISIsis Pharmaceutical licensing partner Antisense reports ATL1103 phase II results
Antisense Therapeutics, or ANP, reported the primary efficacy results from its phase II clinical trial of ATL1103 in patients with the potentially life threatening growth disorder, acromegaly. The phase II trial met its primary efficacy endpoint showing a statistically significant average reduction in the serum insulin-like growth factor-I, or sIGF-1, levels of 26% from baseline at week 14 at the 400mg per week dose tested. All patients treated with 400mg per week of ATL1103 had a reduction in sIGF-I levels from baseline at week 14. Greater reductions in sIGF-I were observed in patients who had lower body weights and thereby received a relatively higher dose per kg bodyweight with the patients who received 5.5 mg/kg per week showing a 36% average reduction in their sIGF-I levels. The positive results achieved in this Phase II trial position ATL1103 to move into Phase III stage of development. Consequently, ANP will accelerate out-licencing activities to secure a pharmaceutical development partner for the drug's further development. ANP has 4 products in its development pipeline that it has in-licensed from Isis Pharmaceuticals, including ATL1103.
07:15 EDTCNATConatus initiates exploratory Phase 2 trial in cirrhosis patients with PH
Subscribe for More Information
07:12 EDTCNATConatus initiates Phase 2 trial in patients with liver cirrhosis
Subscribe for More Information
September 1, 2014
13:48 EDTPLXProtalix to host conference call
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use